SCHEMBL5136558

SCHEMBL5136558

Cc1ccc(CN(CCC(C)C)Cc2cnc(-c3ccccc3)n2CCc2ccccc2)cc1I

nearest known ligand 0.35

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.35
OPRM1 P35372 3/20 0.35
OPRD1 P41143 3/20 0.35
OPRK1 P41145 3/20 0.35
CASR P41180 1/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
KMT2A Q03164 1/20 0.31
HSD11B1 P28845 2/20 0.31
CYP3A4 P08684 1/20 0.30
ALDH1A1 P00352 1/20 0.30
TSHR P16473 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5245866 0.86 OPRM1 (0.38) BCHEOPRM1OPRD1OPRK1CASR
SCHEMBL5137499 0.86 HSD11B1 (0.36) BCHEOPRM1OPRD1OPRK1CASR
SCHEMBL5152777 0.81 OPRM1 (0.36) BCHEOPRM1OPRD1OPRK1CASR
SCHEMBL5153427 0.80 MEN1 (0.37) BCHEOPRM1OPRD1OPRK1CASR
SCHEMBL5135358 0.76 HSD11B1 (0.42) BCHEOPRM1OPRD1OPRK1HSD11B1
SCHEMBL5075147 0.74 TSHR (0.39) MEN1KMT2AHSD11B1CYP3A4ALDH1A1
SCHEMBL5136725 0.74 C5AR1 (0.55) LMNAALDH1A1TSHR
SCHEMBL5135094 0.73 HSD11B1 (0.40) BCHEOPRM1OPRD1OPRK1HSD11B1
SCHEMBL5136922 0.73 KDM4E (0.35) CYP3A4ALDH1A1TSHR
SCHEMBL5136012 0.73 MEN1 (0.39) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed